Skip to main content
Fig. 1 | Respiratory Research

Fig. 1

From: Inositol possesses antifibrotic activity and mitigates pulmonary fibrosis

Fig. 1

Differential metabolic pathways and metabolites between normal and IPF lung fibroblasts. A Partial least-squares discriminant analysis (PLS-DA) of the metabolite values across normal (green) and IPF (pink) primary lung fibroblasts. B Top 25 ranking enriched differential metabolic pathways between normal and IPF primary lung fibroblasts identified by Metabolite Set Enrichment Analysis (MSEA). C Significantly differential metabolites between normal and IPF primary lung fibroblasts. Orange: higher abundance in IPF fibroblasts. Green: higher abundance in normal fibroblasts. D Metabolic alterations of glycolysis, TCA cycle and urea cycle between normal and IPF primary lung fibroblasts. Color-coded metabolites correspond to the fold changes between normal and IPF lung fibroblasts. GLC glucose, G6P glucose 6-phosphate, G3P glyceraldehyde 3-phosphate, 3PG 3-phosphoglycerate, 2,3-BPG 2,3-Bisphosphoglyceric acid, PEP phosphoenolpyruvate, PYR pyruvate, FRU fructose, F1P fructose 1-phosphate, Ru5P ribulose-5-phosphate, MAN Mannose, SER serine, LYS lysine, α-AAA α-aminoadipic acid, CIT citrate, α-KG α-ketoglutarate, GLN glutamine, 2-HG 2-hydroxyglutarate, SSA succinic semialdehyde, FUM fumarate, ASP aspartate, ASN asparagine, ORN ornithine, 4HyP 4-hydroxyproline; PUT putrescine, SPD spermidine, SPR spermine. E The abundance of inositol in normal and IPF lung fibroblasts was determined by using inositol assays (mean ± SE, n = 3, *p < 0.05 versus Normal-2). F mRNA expression levels of the enzymes involved in inositol biosynthesis (INPP4A, IMPA2, and ISYNA1), inositol catabolism and phosphatidylinositol metabolism (MIOX and CDIPT), and inositol transporters (SLC2A13, SLC5A3, and SLC5A11) were measured by RT-qPCR analysis (mean ± SE, n = 3; *p < 0.05 versus Normal-2)

Back to article page